Risperidone内用液の錐体外路症状発現に関する検討

概要

論文の詳細を見る
Though it has been reported that the incidence of extrapyramidal symptoms with risperidone oral solution is lower than that for risperidone tablets, there has still been no detailed comparision of the 2 dosage forms in this respect. With this in mind, we investigated the usage of anti-parkinsonism drugs for a Period of l month from starting to take risperidone oral solution or tablets, and compared the incidence of extrapyramidal symptoms between a risperidone oral solution group of subjects and a tablets group. The incidence of extrapyramidal symptoms for the oral solution group (4.8%) was significantly lower than that for the tablets group (23.2%) (p=0.022; Χ^2-test)(p=0.011; Log rank test) and the number needed to treat was 5.4. From this, we concluded that risperidone oral solution is safer to use than risperidone tablets in virew of the lower incidence of extrapyramidal symptoms.
日本医療薬学会の論文
2007-05-10